Cargando…

Rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed RALPPS stage-1 in patients with cirrhosis-related hepatocellular carcinoma

BACKGROUND: The future liver remnant (FLR) faces a risk of poor growth in patients with cirrhosis-related hepatocellular carcinoma (HCC) after stage-1 radiofrequency-assisted ALPPS (RALPPS). The present study presents a strategy to trigger further FLR growth using supplementary radiofrequency ablati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiang, Chen, Shu, Yan, Jun, Brismar, Torkel, Sparrelid, Ernesto, Qu, Chengming, Ji, Yujun, Chen, Shihan, Ma, Kuansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132340/
https://www.ncbi.nlm.nih.gov/pubmed/34006263
http://dx.doi.org/10.1186/s12893-021-01241-z
_version_ 1783694894718517248
author Wang, Qiang
Chen, Shu
Yan, Jun
Brismar, Torkel
Sparrelid, Ernesto
Qu, Chengming
Ji, Yujun
Chen, Shihan
Ma, Kuansheng
author_facet Wang, Qiang
Chen, Shu
Yan, Jun
Brismar, Torkel
Sparrelid, Ernesto
Qu, Chengming
Ji, Yujun
Chen, Shihan
Ma, Kuansheng
author_sort Wang, Qiang
collection PubMed
description BACKGROUND: The future liver remnant (FLR) faces a risk of poor growth in patients with cirrhosis-related hepatocellular carcinoma (HCC) after stage-1 radiofrequency-assisted ALPPS (RALPPS). The present study presents a strategy to trigger further FLR growth using supplementary radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI). METHODS: At RALPPS stage-1 the portal vein branch was ligated, followed by intraoperative RFA creating a coagulated avascular area between the FLR and the deportalized lobes. During the interstage period, patients not achieving sufficient liver size (≥ 40%) within 2–3 weeks underwent additional percutaneous RFA/PEI of the deportalized lobes (rescue RFA/PEI) in an attempt to further stimulate FLR growth. RESULTS: Seven patients underwent rescue RFA/PEI after RALPPS stage-1. In total five RFAs and eight PEIs were applied in these patients. The kinetic growth rate (KGR) was highest the first week after RALPPS stage-1 (10%, range − 1% to 15%), and then dropped to 1.5% (0–9%) in the second week (p < 0.05). With rescue RFA/PEI applied, KGR increased significantly to 4% (2–5%) compared with that before the rescue procedures (p < 0.05). Five patients proceeded to RALPPS stage-2. Two patients failed: In one patient the FLR remained at a constant level even after four rescue PEIs. The other patient developed metastasis. Except one patient died after RALPPS stage-2, no severe complications (Clavien-Dindo ≥ IIIb) occurred among remaining six patients. CONCLUSIONS: Rescue RFA/PEI may provide an alternative to trigger further growth of the FLR in patients with cirrhosis-related HCC showing insufficient FLR after RALPPS stage-1. Trial registration Retrospectively registered.
format Online
Article
Text
id pubmed-8132340
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81323402021-05-19 Rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed RALPPS stage-1 in patients with cirrhosis-related hepatocellular carcinoma Wang, Qiang Chen, Shu Yan, Jun Brismar, Torkel Sparrelid, Ernesto Qu, Chengming Ji, Yujun Chen, Shihan Ma, Kuansheng BMC Surg Research BACKGROUND: The future liver remnant (FLR) faces a risk of poor growth in patients with cirrhosis-related hepatocellular carcinoma (HCC) after stage-1 radiofrequency-assisted ALPPS (RALPPS). The present study presents a strategy to trigger further FLR growth using supplementary radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI). METHODS: At RALPPS stage-1 the portal vein branch was ligated, followed by intraoperative RFA creating a coagulated avascular area between the FLR and the deportalized lobes. During the interstage period, patients not achieving sufficient liver size (≥ 40%) within 2–3 weeks underwent additional percutaneous RFA/PEI of the deportalized lobes (rescue RFA/PEI) in an attempt to further stimulate FLR growth. RESULTS: Seven patients underwent rescue RFA/PEI after RALPPS stage-1. In total five RFAs and eight PEIs were applied in these patients. The kinetic growth rate (KGR) was highest the first week after RALPPS stage-1 (10%, range − 1% to 15%), and then dropped to 1.5% (0–9%) in the second week (p < 0.05). With rescue RFA/PEI applied, KGR increased significantly to 4% (2–5%) compared with that before the rescue procedures (p < 0.05). Five patients proceeded to RALPPS stage-2. Two patients failed: In one patient the FLR remained at a constant level even after four rescue PEIs. The other patient developed metastasis. Except one patient died after RALPPS stage-2, no severe complications (Clavien-Dindo ≥ IIIb) occurred among remaining six patients. CONCLUSIONS: Rescue RFA/PEI may provide an alternative to trigger further growth of the FLR in patients with cirrhosis-related HCC showing insufficient FLR after RALPPS stage-1. Trial registration Retrospectively registered. BioMed Central 2021-05-18 /pmc/articles/PMC8132340/ /pubmed/34006263 http://dx.doi.org/10.1186/s12893-021-01241-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Qiang
Chen, Shu
Yan, Jun
Brismar, Torkel
Sparrelid, Ernesto
Qu, Chengming
Ji, Yujun
Chen, Shihan
Ma, Kuansheng
Rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed RALPPS stage-1 in patients with cirrhosis-related hepatocellular carcinoma
title Rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed RALPPS stage-1 in patients with cirrhosis-related hepatocellular carcinoma
title_full Rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed RALPPS stage-1 in patients with cirrhosis-related hepatocellular carcinoma
title_fullStr Rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed RALPPS stage-1 in patients with cirrhosis-related hepatocellular carcinoma
title_full_unstemmed Rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed RALPPS stage-1 in patients with cirrhosis-related hepatocellular carcinoma
title_short Rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed RALPPS stage-1 in patients with cirrhosis-related hepatocellular carcinoma
title_sort rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed ralpps stage-1 in patients with cirrhosis-related hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132340/
https://www.ncbi.nlm.nih.gov/pubmed/34006263
http://dx.doi.org/10.1186/s12893-021-01241-z
work_keys_str_mv AT wangqiang rescueradiofrequencyablationorpercutaneousethanolinjectionastrategyforfailedralppsstage1inpatientswithcirrhosisrelatedhepatocellularcarcinoma
AT chenshu rescueradiofrequencyablationorpercutaneousethanolinjectionastrategyforfailedralppsstage1inpatientswithcirrhosisrelatedhepatocellularcarcinoma
AT yanjun rescueradiofrequencyablationorpercutaneousethanolinjectionastrategyforfailedralppsstage1inpatientswithcirrhosisrelatedhepatocellularcarcinoma
AT brismartorkel rescueradiofrequencyablationorpercutaneousethanolinjectionastrategyforfailedralppsstage1inpatientswithcirrhosisrelatedhepatocellularcarcinoma
AT sparrelidernesto rescueradiofrequencyablationorpercutaneousethanolinjectionastrategyforfailedralppsstage1inpatientswithcirrhosisrelatedhepatocellularcarcinoma
AT quchengming rescueradiofrequencyablationorpercutaneousethanolinjectionastrategyforfailedralppsstage1inpatientswithcirrhosisrelatedhepatocellularcarcinoma
AT jiyujun rescueradiofrequencyablationorpercutaneousethanolinjectionastrategyforfailedralppsstage1inpatientswithcirrhosisrelatedhepatocellularcarcinoma
AT chenshihan rescueradiofrequencyablationorpercutaneousethanolinjectionastrategyforfailedralppsstage1inpatientswithcirrhosisrelatedhepatocellularcarcinoma
AT makuansheng rescueradiofrequencyablationorpercutaneousethanolinjectionastrategyforfailedralppsstage1inpatientswithcirrhosisrelatedhepatocellularcarcinoma